Manju Sengar

Manju Sengar

Auto-generated profile, based on publicly available information

Manju Sengar

Department of Medical Oncology, Tata Memorial Centre, Mumbai, India

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2022 in Nature Reviews Clinical Oncology
Verified
Journal Article
Closed access
PDF file
CBCarlos Barrios
Carlos Barrios
Gilberto De Lima LopesGilberto De Lima Lopes
Gilberto De Lima Lopes
MYMastura Md Yusof
Mastura Md Yusof
FRFidel Rubagumya
Fidel Rubagumya
Piotr RutkowskiPiotr Rutkowski
Piotr Rutkowski
MSManju Sengar
Manju Sengar

26 February 2021 in Blood Advances
Verified
Journal Article
Open access
PDF file
ARAkhil Rajendra
Akhil Rajendra
HJHasmukh Jain
Hasmukh Jain
VBV. N. Avinash Bonda
V. N. Avinash Bonda
LNLingaraj Nayak
Lingaraj Nayak
PTPrashant Tembhare
Prashant Tembhare
MSManju Sengar
Manju Sengar
The use of pediatrics-inspired protocols in adolescent and young adult (AYA) acute lymphoblastic leukemia (ALL) results in superior survival compared with the adult protocols. Pediatrics-inspired protocols carry an increased risk of toxicity and treatment-related mortality in low resource settings, which can offset the potential benefits. We studied the outcomes and prognostic factors in the treatment of AYA ALL with a pediatrics-inspired regimen. We retrieved data regarding demographics, investigations, treatment details, and toxicities from the electronic medical records of patients diagnosed with ALL in the 15- to 25-year-old age group who were initiated on a modified Berlin-Frankfurt-Münster 90 (BFM-90) protocol between January 2013 and December 2016 at the Tata Memorial Centre. A total of 349 patients in the 15- to 25-year-old age group were treated with a modified BFM-90 protocol. The use of this pediatrics-inspired protocol resulted in a 3-year event-free survival (EFS) and overall survival (OS) of 59.4% and 61.8%, respectively. Only 15 patients underwent an allogeneic stem cell transplant. Minimal residual disease (MRD) persistence postinduction emerged as the only factor predictive of poor outcomes. A modified BFM-90 protocol is an effective and safe regimen for AYA ALL with an OS and EFS comparable to the published literature.

18 January 2021 in Indian Journal of Critical Care Medicine
Verified
Journal Article
Open access
MSManju Sengar
Manju Sengar
VBVikas Bhagat
Vikas Bhagat
SAShwetha Ambapurkar
Shwetha Ambapurkar
The number of allogeneic solid organ and bone marrow transplants is increasing all over the world. To prevent transplant rejection and treat acute rejection of transplant, immunosuppressant drugs are used. The outcomes of solid organ transplants have dramatically improved over last 30 years, due to availability of multiple immunosuppressive agents, with varied mechanisms of action. The use of intense immunosuppression makes the individual having undergone solid organ transplant at the risk of several serious infections, which may prove fatal. To prevent and treat these infections (when they occur), patients are often given antimicrobial prophylaxis and therapy. The use of antimicrobials can interfere with the metabolism of the immunosuppressants, and may put the patient at risk of developing severe adverse effects due to unwanted increase or decrease in the serum levels of immunosuppressive agents. Knowledge of these interactions is essential for successful management of solid organ transplant patients. We therefore decided to review the literature and present the interactions that commonly occur between these two life-saving groups of drugs.

1 January 2019 in Indian Journal of Medical and Paediatric Oncology
Verified
Journal Article
Open access
PDF file
MSManju Sengar
Manju Sengar
AFAdam Fundytus
Adam Fundytus
WHWilma M. Hopman
Wilma M. Hopman
HMHemant Malhotra
Hemant Malhotra
SGSudeep Gupta
Sudeep Gupta
CBChristopher M. Booth
Christopher M. Booth
Background: The growing burden of cancer within India has implications across the health system including operational delivery of cancer care and planning for human health resources. Here, we report the Indian results of a global survey of medical oncology (MO) workload in comparison to medical oncologists (MOs) in other low-middle- income countries (LMICs). Methods: An online survey was distributed through a snowball method through national oncology societies to chemotherapy-prescribing physicians in 22 LMICs. The survey was distributed to Indian MOs by the Indian Society of Medical and Pediatric Oncology and the National Cancer Grid of India. The workload was measured as the annual number of new cancer patient consults seen per oncologist. Results: One hundred and forty-seven oncologists from LMICs completed the survey; 82 from India and 65 from other LMICs. About 59% (48/82) of Indian MOs reported working exclusively in the private health system compared to 23% (15/65) of MOs in other LMICs (P < 0.001). The median number of annual consults per MO was 475 in India compared with 350 in other LMICs. The proportion of MOs seeing >1000 new consults/year was 24% (20/82) in India and 20% (13/65) in other LMICs (P = 0.530). The median number of patients seen in a full-day clinic was 35 in India and 25 in other LMCs (P = 0.003); 26% of Indian MO reported seeing >50 patients per day. Compared to other LMICs, Indian MOs worked more days/week (median 6 vs. 5, P < 0.001) and hours/week (median 51–60 vs. 41–50, P = 0.004) and had less annual leave for vacation (3 weeks vs. 4, P = 0.017). Conclusion: Indian MOs have higher clinical volumes and workload than MOs in other LMICs and substantially higher workload than MOs in high-income countries. Indian health policymakers should consider alternative models of care and increasing MO workforce supply to address the growing burden of cancer.

16 August 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
Dario TrapaniDario Trapani
Dario Trapani
KTKiu Tay-Teo
Kiu Tay-Teo
MTMegan E Tesch
Megan E Tesch
FRFelipe Roitberg
Felipe Roitberg
MSManju Sengar
Manju Sengar
GCGiuseppe Curigliano
Giuseppe Curigliano
Background: Advances in cancer medicines have resulted in tangible health impacts, but the magnitude of benefits of approved cancer medicines could vary greatly. Health Technology Assessment (HTA) is a multidisciplinary process used to inform resource allocation through a systematic value assessment of health technology. This paper reviews the challenges in conducting HTA for cancer medicines arising from oncology trial designs and uncertainties of safety-efficacy data. Methods: Multiple databases (PubMed, Scopus and Google Scholar) and grey literature (public health agencies and governmental reports) were searched to inform this policy narrative review. Results: A lack of robust efficacy-safety data from clinical trials and other relevant sources of evidence has made HTA for cancer medicines challenging. The approval of cancer medicines through expedited pathways has increased in recent years, in which surrogate endpoints or biomarkers for patient selection have been widely used. Using these surrogate endpoints has created uncertainties in translating surrogate measures into patient-centric clinically (survival and quality of life) and economically (cost-effectiveness and budget impact) meaningful outcomes, with potential effects on diverting scarce health resources to low-value or detrimental interventions. Potential solutions include policy harmonization between regulatory and HTA authorities, commitment to generating robust post-marketing efficacy-safety data, managing uncertainties through risk-sharing agreements, and using value frameworks. Conclusion: A lack of robust efficacy-safety data is a central problem for conducting HTA of cancer medicines, potentially resulting in misinformed resource allocation.

3 March 2021 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
PGPrasanth Ganesan
Prasanth Ganesan
HJHasmukh Jain
Hasmukh Jain
BBBhausaheb Bagal
Bhausaheb Bagal
PSPapagudi G. Subramanian
Papagudi G. Subramanian
BGBiju George
Biju George
MSManju Sengar
Manju Sengar
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.